Semaglutide
Treatment for Chronic Kidney Disease Due To Diabetes Mellitus Type 2
Typical Dosage: Semaglutide 0.5-2mg weekly (SC)
Effectiveness
85%
Safety Score
60%
Clinical Trials
10
Participants
100K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
Semaglutide 0.5-2mg weekly (SC)
Time to Effect
6-12 months for sustained renal/CV benefits
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
45(Treat 45 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
10(Treat 10 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$11,500
Monitoring:$1,200
Side Effect Mgmt:$200
Total Annual:$12,900
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$140,000/QALY
QALYs Gained
0.6
Outcome-Based Costs
Cost per Responder
$18,428.57
Comparison vs ACE inhibitor/ARB alone
Cost Difference
+$11,500/year
More expensive
QALY Difference
+0.50 QALYs
Better outcomes
Dominance
No dominance
Semaglutide Outcomes
for Chronic Kidney Disease Due To Diabetes Mellitus Type 2
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+70%
Common Side Effects
Nausea
+30%
Vomiting
+15%
Diarrhea
+15%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov